Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise NEW YORK and SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten and advance the company's expanding cardiovascular pipeline while diversifying access to capital as the ...

Group 1 - Cytokinetics plans to offer approximately $500 million of its common stock in an underwritten public offering, subject to market conditions [1] - The company expects to grant underwriters a 30-day option to purchase up to an additional 15% of the shares sold in the offering [1] - All shares in the offering will be sold by Cytokinetics [1] Group 2 - J.P. Morgan, Goldman Sachs & Co. LLC, and Morgan Stanley are acting as sole joint book-running managers for the offering [2] - The offering is being conducted under a shelf registration statement filed with the SEC on November 18, 2022, which has become automatically effective [3] Group 3 - Cytokinetics is a late-stage biopharmaceutical company focused on developing muscle activators and inhibitors for diseases affecting muscle performance [5]

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, approximately $500 million of shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Cytokinetics expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of sha ...

Core Viewpoint - Cytokinetics and Royalty Pharma have entered into a strategic funding collaboration to support the commercialization of aficamten and advance Cytokinetics' cardiovascular pipeline, providing up to $575 million in total funding [1][2][5] Group 1: Funding Details - Cytokinetics will receive $50 million upfront for a Phase 2 clinical trial of CK-586, with Royalty Pharma having the option to invest an additional $150 million for Phase 3 development [3] - The collaboration includes $50 million for the commercial launch of aficamten, with an additional $175 million available within 12 months of FDA approval, repayable over 10 years [4] - Royalty Pharma's royalty on aficamten has been restructured to 4.5% on annual net sales up to $5 billion and 1% above that threshold [4] Group 2: Clinical Development - Aficamten has shown a positive clinical profile in its pivotal Phase 3 study and is expected to improve the lives of patients with hypertrophic cardiomyopathy (HCM) if approved by the FDA [2][9] - Cytokinetics plans to submit a New Drug Application (NDA) for aficamten in Q3 2024 and a Marketing Authorization Application (MAA) in Q4 2024 [9] - The company is also advancing CK-586 to a Phase 2 trial for heart failure with preserved ejection fraction (HFpEF), expected to begin in Q4 2024 [14] Group 3: Company Background - Cytokinetics is a late-stage biopharmaceutical company focused on developing muscle activators and inhibitors for cardiac diseases [15] - The company is preparing for regulatory submissions for aficamten and is also developing omecamtiv mecarbil and CK-586 for various heart failure indications [15] - Royalty Pharma is a leading funder of biopharmaceutical innovation, collaborating with various companies to support late-stage clinical trials and new product launches [17]

SOUTH SAN FRANCISCO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) announced that the Company will host the muscle biology-focused Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) today, May 17th, 2024 at the Mission Bay Conference Center in San Francisco. This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update the ...

Core Insights - Cytokinetics is hosting the Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) to foster collaboration and innovation in muscle biology research [1][2] - The company is focused on developing first-in-class muscle activators and next-in-class muscle inhibitors for treating diseases related to cardiac muscle performance [3] Company Overview - Cytokinetics is a late-stage biopharmaceutical company specializing in cardiovascular treatments, particularly targeting muscle performance [3] - The company is preparing for regulatory submissions for aficamten, a cardiac myosin inhibitor, following positive results from the SEQUOIA-HCM Phase 3 clinical trial [3] - Other ongoing clinical trials for aficamten include MAPLE-HCM, ACACIA-HCM, CEDAR-HCM, and FOREST-HCM, focusing on various patient populations with hypertrophic cardiomyopathy [3] - Cytokinetics is also developing omecamtiv mecarbil for heart failure and CK-586 and CK-136 for different types of heart failure [3] Event Details - The CLIMB symposium aims to bring together scientists and researchers to share innovative research and promote interdisciplinary dialogue in muscle biology [2] - The event features expert speakers and poster presentations, enhancing networking opportunities within the muscle biology community [2][4]

Title: Effect of Aficamten on Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The SEQUOIA-HCM CMR Substudy Presenter: Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University Date: Augst 30, 2024 Topic: Infiltrative Myocardial Disease Session Title: Cardiac Amyloidosis: Diagnosis and Outcomes Session Type: Moderated ePosters Session Time: 3:00-3:50 PM BST Location: Station 10 Title: Clinical Application of Biomarkers in ...

Analyses of SEQUOIA-HCM Elaborate on Dosing and Measures of Safety During Treatment with Aficamten Results from Cardiopulmonary Exercise Testing Showed Improvement in Exercise Performance were Strongly Correlated to Other Measures of Clinical Improvement Company to Host Investor Event and Webcast Today at 4:00 PM Western European Summer Time (11:00 AM Eastern Time) SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that additional results ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50633 CYTOKINETICS, INCORPORATED (Exact name of registrant as specified in its charter) Delaware 94-3291317 (State or other jur ...

Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Diane Weiser - SVP of Corporate Communication and IR Robert Blum - President and CEO Fady Malik - EVP of R&D Stuart Kupfer - SVP and Chief Medical Officer Andrew Callos - EVP and Chief Commercial Officer Robert Wong - VP and Chief Accounting Officer Conference Call Participants Paul Choi - Goldman Sachs Srikripa Devarakonda - Truist Securities Tessa Romero - JPMorgan Roanna Ruiz - Leerink Sa ...